A biologic designed for the treatment of inflammatory diseases, Siliq (brodalumab), has been approved by the U.S. Food and Drug Administration (FDA) to treat adults with moderate-to-severe plaque psoriasis.
Due ... Read more
The U.S. Food and Drug Administration (FDA) has approved Perrigo’s generic version of Topicort (desoximetasone topical spray, 0.25%) to treat plaque psoriasis, the company announced. Topicort, owned by Taro Pharmaceuticals US, is ... Read more
Cellceutix, a clinical stage biopharma that develops novel therapies for oncology, dermatology, anti-inflammatory, and antibiotic applications, is announcing the institution of a “Database Soft Lock” as well as key additional ... Read more
The U.S. FDA recently approved a new drug, Taltz (ixekizumab), for the treatment of patients suffering from moderate-to-severe plaque psoriasis. Psoriasis is a long-lasting autoimmune disease characterized by patches ... Read more
Pin It on Pinterest